Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

Supplementary biologics license application planned for submission to the U.S. Food and Drug Administration in the first quarter of 2025 “All currently FDA-approved anti-VEGF therapies for retinal ...

ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...

Feb. 6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two treatments per ...

Celltrion, Inc. announced that the US Food and Drug Administration (FDA) has approved Eydenzelt (aflibercept-boav), biosimilar referencing Eylea (aflibercept), for the treatment of neovascular (wet) ...

ORLANDO, Fla. — The old, generic cholesterol drug fenofibrate has shown potential for slowing the progression of diabetic retinopathy in people with early retinal changes, with the potential to reduce ...

The Food and Drug Administration approved Genentech’s drug Lucentis to treat all forms of diabetic retinopathy — a complication of diabetes that leads to vision loss. Lucentis represents the first FDA ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...